Compare CVS Health Corp (CVS) vs Vale SA (VALE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
CVS Health Corp vs Vale SA — how do they compare? CVS Health Corp trades at $86.25 (market cap $112.49B), while Vale SA trades at $13.48 (market cap $58.70B). The key difference: CVS Health Corp is the larger of the two by market cap, and Vale SA pays the higher dividend (8.75%). Which is the better fit depends on your goals — on Pluang, investors hold CVS Health Corp for 83 Days and Vale SA for 109 Days on average.
| CVS | VALE | |
|---|---|---|
Market Cap | $112.49B | $58.70B |
Volume | 8,467,392 | 45,073,516 |
Sector | Health | Basic Materials |
52-Week High | $110.60 | $17.82 |
52-Week Low | $70.08 | $10.75 |
Typical Hold Time | 83 Days | 109 Days |
Enterprise Value | $174.83B | $74.94B |
Dividend Yield | 3.02% | 8.75% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CVS Health trades at $87.80, up 1.59% today, with strong analyst support (85% buy ratings) and a $111.20 consensus price target suggesting 27% upside. Recent quarterly earnings have consistently beaten expectations, with Q2 2026 EPS of $2.58 surpassing the $1.87 estimate. Revenue growth remains solid, reaching $402.07B in 2025, though net margins compressed to 1.18%. The technical picture shows bullish momentum with current price near key support at $87.
CVS presents a compelling value opportunity with attractive valuation multiples (P/E 23.21, P/S 0.27) and dividend stability, but faces margin pressure from healthcare cost trends. The stock's upside depends on maintaining earnings momentum amid reimbursement challenges and regulatory scrutiny highlighted in recent legal investigations.
VALE trades at $13.42, down 4.69% today amid broader sector weakness. The stock shows bearish technical signals with recent earnings misses and declining profit margins (5.11% net margin in 2025). Revenue has stabilized around $38-41B, but net income fell to $2.35B in 2025 from $18.8B in 2022. The company maintains strong cash flow generation ($8.8B operating cash flow) and recently declared a $0.40 dividend payable September 2026.
VALE faces headwinds from iron ore price volatility and rising costs, but base metals growth provides diversification. Analyst consensus is mixed with 32% buy ratings and a $16.21 price target suggesting 21% upside. Key risks include Brazilian regulatory exposure and cyclical commodity dependence. The current valuation (P/E 27.22) appears stretched given earnings compression.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About CVS Health Corp
Following its acquisition of Aetna in late 2018, CVS Health now provides an even more integrated healthcare-services offering for its members. Legacy CVS combined both the largest pharmacy benefit manager, processing over 2 billion adjusted claims annually, and a sizable pharmacy operation, including nearly 10,000 retail pharmacy locations primarily in the U.S. Adding a managed-care organization with 24 million medical members gives the company a strong position in the insurance industry and should help CVS better control overall healthcare costs for its clients.
Read more on CVS →About Vale SA
Vale is the world's largest iron ore miner and one of the largest diversified miners, along with BHP and Rio Tinto. Earnings are dominated by the bulk materials division, primarily iron ore and iron ore pellets, with minor contributions from iron ore proxies, including manganese and coal. The base metals division is much smaller, primarily consisting of nickel mines and smelters with a small contribution from copper.
Read more on VALE →
